New Lung Cancer Pill Reduces Death Risk by 50% in Clinical Trial
A global study has shown that a once-daily pill, osimertinib, reduces the risk of dying from lung cancer by over half. Taken after tumor-removal surgery, the drug was shown to lessen the risk of patient death by 51 percent worldwide. The non-placebo group observed a survival rate of 88 percent after five years, compared to the placebo group, which saw a markedly lower survival rate of 78 percent. The drug is effective for patients with a mutated EGFR gene, present in roughly a quarter of lung cancer cases worldwide.